David A Morrow

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. ncbi Usefulness of tirofiban among patients treated without percutaneous coronary intervention (TIMI high risk patients in PRISM-PLUS)
    David A Morrow
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    Am J Cardiol 94:774-6. 2004
  2. ncbi Angiography and revascularization in patients with heart failure following fibrinolytic therapy for ST-elevation acute myocardial infarction
    Amir Kashani
    Rochester General Hospital, Rochester, New York, USA
    Am J Cardiol 95:228-33. 2005
  3. ncbi Predictors of the rise in vWF after ST elevation myocardial infarction: implications for treatment strategies and clinical outcome: An ENTIRE-TIMI 23 substudy
    Kausik K Ray
    TIMI Study Group and Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital Harvard Medical School, Boston, MA, USA
    Eur Heart J 26:440-6. 2005
  4. ncbi Efficacy and safety of vorapaxar in patients with prior ischemic stroke
    David A Morrow
    Brigham and Women s Hospital, Boston, MA 02115, USA
    Stroke 44:691-8. 2013
  5. ncbi Vorapaxar in the secondary prevention of atherothrombotic events
    David A Morrow
    Thrombolysis in Myocardial Infarction TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
    N Engl J Med 366:1404-13. 2012
  6. ncbi The Risk Score Profile: a novel approach to characterising the risk of populations enrolled in clinical studies
    David A Morrow
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA
    Eur Heart J 25:1139-45. 2004
  7. ncbi One-year outcomes after a strategy using enoxaparin vs. unfractionated heparin in patients undergoing fibrinolysis for ST-segment elevation myocardial infarction: 1-year results of the ExTRACT-TIMI 25 trial
    David A Morrow
    TIMI Study Group Cardiovascular Division, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    Eur Heart J 31:2097-102. 2010
  8. ncbi Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial
    David A Morrow
    TIMI Study Group, Department of Medicine, Brigham and Women s Hospital, and Harvard Medical School, Boston, Mass 02115, USA
    JAMA 297:1775-83. 2007
  9. ncbi Evaluation of the AccuTnI cardiac troponin I assay for risk assessment in acute coronary syndromes
    David A Morrow
    Department of Medicine and TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, 75 Francis St, Boston, MA 02115, USA
    Clin Chem 49:1396-8. 2003
  10. ncbi Evaluation of the glycometabolic effects of ranolazine in patients with and without diabetes mellitus in the MERLIN-TIMI 36 randomized controlled trial
    David A Morrow
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
    Circulation 119:2032-9. 2009

Detail Information

Publications103 found, 100 shown here

  1. ncbi Usefulness of tirofiban among patients treated without percutaneous coronary intervention (TIMI high risk patients in PRISM-PLUS)
    David A Morrow
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    Am J Cardiol 94:774-6. 2004
    ..8% vs 21.9%; odds ratio [OR] 0.69, p = 0.04). This benefit was similar in magnitude as that for patients who underwent PCI (32.4% vs 22.2%; OR 0.60, p = 0.06). No benefit was evident in low-risk patients...
  2. ncbi Angiography and revascularization in patients with heart failure following fibrinolytic therapy for ST-elevation acute myocardial infarction
    Amir Kashani
    Rochester General Hospital, Rochester, New York, USA
    Am J Cardiol 95:228-33. 2005
    ....
  3. ncbi Predictors of the rise in vWF after ST elevation myocardial infarction: implications for treatment strategies and clinical outcome: An ENTIRE-TIMI 23 substudy
    Kausik K Ray
    TIMI Study Group and Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital Harvard Medical School, Boston, MA, USA
    Eur Heart J 26:440-6. 2005
    ....
  4. ncbi Efficacy and safety of vorapaxar in patients with prior ischemic stroke
    David A Morrow
    Brigham and Women s Hospital, Boston, MA 02115, USA
    Stroke 44:691-8. 2013
    ..We tested the efficacy and safety of vorapaxar in a prespecified analysis in the stroke subcohort from a multinational, randomized, placebo-controlled trial...
  5. ncbi Vorapaxar in the secondary prevention of atherothrombotic events
    David A Morrow
    Thrombolysis in Myocardial Infarction TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
    N Engl J Med 366:1404-13. 2012
    ..Thrombin potently activates platelets through the protease-activated receptor PAR-1. Vorapaxar is a novel antiplatelet agent that selectively inhibits the cellular actions of thrombin through antagonism of PAR-1...
  6. ncbi The Risk Score Profile: a novel approach to characterising the risk of populations enrolled in clinical studies
    David A Morrow
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA
    Eur Heart J 25:1139-45. 2004
    ....
  7. ncbi One-year outcomes after a strategy using enoxaparin vs. unfractionated heparin in patients undergoing fibrinolysis for ST-segment elevation myocardial infarction: 1-year results of the ExTRACT-TIMI 25 trial
    David A Morrow
    TIMI Study Group Cardiovascular Division, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    Eur Heart J 31:2097-102. 2010
    ..To determine the impact of a strategy using enoxaparin for up to 8 days compared with unfractionated heparin (UFH) for 48 h as an adjunct to fibrinolysis for ST-segment elevation myocardial infarction (STEMI) on 1-year clinical outcomes...
  8. ncbi Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial
    David A Morrow
    TIMI Study Group, Department of Medicine, Brigham and Women s Hospital, and Harvard Medical School, Boston, Mass 02115, USA
    JAMA 297:1775-83. 2007
    ..Ranolazine is a novel antianginal agent that reduces ischemia in patients with chronic angina but has not been studied in patients with acute coronary syndromes (ACS)...
  9. ncbi Evaluation of the AccuTnI cardiac troponin I assay for risk assessment in acute coronary syndromes
    David A Morrow
    Department of Medicine and TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, 75 Francis St, Boston, MA 02115, USA
    Clin Chem 49:1396-8. 2003
  10. ncbi Evaluation of the glycometabolic effects of ranolazine in patients with and without diabetes mellitus in the MERLIN-TIMI 36 randomized controlled trial
    David A Morrow
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
    Circulation 119:2032-9. 2009
    ..We designed a prospective evaluation of the effect of ranolazine on hyperglycemia as part of a randomized, double-blind, placebo-controlled outcomes trial...
  11. ncbi Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardi
    David A Morrow
    Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
    Circulation 119:2758-64. 2009
    ..This effect must be balanced against an increased bleeding risk. We aimed to characterize the effect of prasugrel with respect to the type, size, and timing of MI using the universal classification of MI...
  12. ncbi Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18
    David A Morrow
    Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 41:1264-72. 2003
    ....
  13. ncbi A randomized, placebo-controlled trial to evaluate the tolerability, safety, pharmacokinetics, and pharmacodynamics of a potent inhibitor of poly(ADP-ribose) polymerase (INO-1001) in patients with ST-elevation myocardial infarction undergoing primary perc
    David A Morrow
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    J Thromb Thrombolysis 27:359-64. 2009
    ..Reperfusion injury is a significant complication of the management of ST-elevation MI (STEMI). INO-1001 is a potent inhibitor of poly(ADP-ribose) polymerase (PARP), a mediator of oxidant-induced myocyte dysfunction during reperfusion...
  14. ncbi Potent inhibition of thrombin with a monoclonal antibody against tissue factor (Sunol-cH36): results of the PROXIMATE-TIMI 27 trial
    David A Morrow
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    Eur Heart J 26:682-8. 2005
    ..Sunol-cH36, a chimaeric monoclonal antibody to TF, blocks binding of factor X to the TF:VIIa complex. This report describes the first completed trial of Sunol-cH36 in humans...
  15. ncbi Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P
    David A Morrow
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
    Am Heart J 158:335-341.e3. 2009
    ..Because SCH 530348 does not interfere with other pathways for hemostasis, it is possible that SCH 530348 reduces thrombosis with less increase in bleeding than do other potent antiplatelet agents...
  16. ncbi Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial
    David A Morrow
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, 75 Francis St, Boston, Massachusetts 02115, USA
    Circulation 114:281-8. 2006
    ..Retrospective analyses suggest that this risk may be modified with statin therapy. However, a role for hsCRP in monitoring the success of therapy remains uncertain...
  17. ncbi B-type natriuretic peptide and the effect of ranolazine in patients with non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary-Thr
    David A Morrow
    Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 55:1189-96. 2010
    ..We designed a prospective evaluation of the interaction between B-type natriuretic peptide (BNP) and the effect of ranolazine in patients with acute coronary syndromes (ACS) as part of a randomized, blinded, placebo-controlled trial...
  18. ncbi Effect of enoxaparin versus unfractionated heparin in diabetic patients with ST-elevation myocardial infarction in the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRAC
    David A Morrow
    Department of Medicine, Harvard Medical School, Boston, MA, USA
    Am Heart J 154:1078-84, 1084.e1. 2007
    ..Potent antithrombotic therapies may offer particular benefit for these high-risk patients and must be balanced against the potential for increased bleeding...
  19. ncbi Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18
    David A Morrow
    TIMI Study Group Cardiovascular Division, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    Eur Heart J 29:1096-102. 2008
    ....
  20. ncbi Extent of ST-segment resolution after fibrinolysis adds improved risk stratification to clinical risk score for ST-segment elevation myocardial infarction
    James R Harkness
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, and Harvard Medical School, Boston, MA 02115, USA
    Am Heart J 159:55-62. 2010
    ..We sought to determine whether STRes provides incremental risk stratification to the TIMI risk score...
  21. ncbi The prognostic value of serum myoglobin in patients with non-ST-segment elevation acute coronary syndromes. Results from the TIMI 11B and TACTICS-TIMI 18 studies
    James A de Lemos
    Thrombolysis in Myocardial Infarction TIMI Study Group, Reynolds Cardiovascular Clinical Research Center, University of Texas Southwestern Medical School, 5323 Harry Hines Boulevard, Dallas, TX 75390 9047, USA
    J Am Coll Cardiol 40:238-44. 2002
    ..The goal of this study was to define the prognostic value of serum myoglobin in patients with non-ST-elevation acute coronary syndromes (ACS)...
  22. ncbi Outcomes of patients with acute coronary syndrome and previous coronary artery bypass grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the Aggrastat to Zocor [A to Z] trials)
    Emmanouil S Brilakis
    Cardiovascular Division, Department of Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA
    Am J Cardiol 102:552-8. 2008
    ..In conclusion, compared with patients with ACS without previous CABG, those with previous CABG have a higher risk for adverse cardiac events and may derive similar benefit from intensive statin therapy...
  23. ncbi Association between thrombolysis in myocardial infarction myocardial perfusion grade, biomarkers, and clinical outcomes among patients with moderate- to high-risk acute coronary syndromes: observations from the randomized trial to evaluate the relative PR
    C Michael Gibson
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Boston, MA, USA
    Am Heart J 152:756-61. 2006
    ..A variety of imaging modalities have implicated impaired myocardial perfusion in the pathogenesis of acute coronary syndromes (ACSs)...
  24. ncbi Implications of upstream glycoprotein IIb/IIIa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction: a comparison of the Thrombolysis In Myocardial Infarction (TIMI) IIIB trial and th
    Marc S Sabatine
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
    Circulation 109:874-80. 2004
    ..We sought to examine the effect of these advances on clinical outcomes and the benefits of an early invasive strategy in UA/NSTEMI...
  25. ncbi Clinical application of C-reactive protein across the spectrum of acute coronary syndromes
    Benjamin M Scirica
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, MA 02461, USA
    Clin Chem 53:1800-7. 2007
    ..The ability to formulate recommendations regarding clinical use of hsCRP is limited by a paucity of data regarding several key issues. The purpose of this study was to evaluate hsCRP across the spectrum of ACS...
  26. ncbi Differential expression of cardiac biomarkers by gender in patients with unstable angina/non-ST-elevation myocardial infarction: a TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombo
    Stephen D Wiviott
    Cardiovascular Division, Brigham and Women s Hospital, 75 Francis St, Boston, Mass 02115, USA
    Circulation 109:580-6. 2004
    ..We sought to examine the relationship between gender and cardiac biomarkers in patients with unstable angina (UA)/non-ST-segment elevation myocardial infarction (NSTEMI)...
  27. ncbi Relationship between baseline white blood cell count and degree of coronary artery disease and mortality in patients with acute coronary syndromes: a TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservati
    Marc S Sabatine
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    J Am Coll Cardiol 40:1761-8. 2002
    ....
  28. ncbi Prospective evaluation of pregnancy-associated plasma protein-a and outcomes in patients with acute coronary syndromes
    Marc P Bonaca
    Brigham and Women s Hospital, Boston, Massachusetts, USA
    J Am Coll Cardiol 60:332-8. 2012
    ..This study sought to investigate whether pregnancy-associated plasma protein-A (PAPP-A) is useful for risk assessment in non-ST-segment elevation acute coronary syndrome (NSTE-ACS)...
  29. ncbi Combined assessment of thrombolysis in myocardial infarction flow grade, myocardial perfusion grade, and ST-segment resolution to evaluate epicardial and myocardial reperfusion
    Robert P Giugliano
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, 350 Longwood Avenue, 1st Floor Offices, Boston, MA 02115, USA
    Am J Cardiol 93:1362-7, A5-6. 2004
    ..This new end point is proposed to evaluate the success of reperfusion therapy in patients who undergo early angiography...
  30. ncbi A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 trial
    C Michael Gibson
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital and Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA
    J Am Coll Cardiol 47:2364-73. 2006
    ....
  31. ncbi Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study
    Benjamin M Scirica
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 47:2326-31. 2006
    ..We aimed to determine whether intensive statin therapy reduces hospitalization for heart failure (HF) in high-risk patients...
  32. ncbi Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes
    James A de Lemos
    TIMI Study Group, Donald W Reynolds Cardiovascular Clinical Research Center, The University of Texas, Southwestern Medical School, Dallas, TX 75390 9047, USA
    Circulation 107:690-5. 2003
    ..MCP-1 appears to play a critical role at multiple stages in atherosclerosis, including the initiation of the fatty streak, promotion of plaque instability, and remodeling after myocardial infarction...
  33. ncbi A strategy of using enoxaparin as adjunctive antithrombin therapy reduces death and recurrent myocardial infarction in patients who achieve early ST-segment resolution after fibrinolytic therapy: the ExTRACT-TIMI 25 ECG study
    Benjamin M Scirica
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, 350 Longwood Avenue, First Floor, Boston, MA 02115, USA
    Eur Heart J 28:2070-6. 2007
    ..To determine the relationship between a strategy of enoxaparin (ENOX), early ST-segment resolution (STRes), and clinical outcomes on patients with ST-segment elevation myocardial infarction (STEMI) after fibrinolysis...
  34. ncbi Association of a pulsatile blood flow pattern on coronary arteriography and short-term clinical outcomes in acute myocardial infarction
    C Michael Gibson
    Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 43:1170-6. 2004
    ....
  35. ncbi Influence of race on death and ischemic complications in patients with non-ST-elevation acute coronary syndromes despite modern, protocol-guided treatment
    Marc S Sabatine
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Boston, Mass 02115
    Circulation 111:1217-24. 2005
    ..Whether the disparate outcomes exist independently of potential biases in treatment patterns remains unclear...
  36. ncbi Evaluation of multiple biomarkers of cardiovascular stress for risk prediction and guiding medical therapy in patients with stable coronary disease
    Marc S Sabatine
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, 350 Longwood Ave, Boston, MA 02115, USA
    Circulation 125:233-40. 2012
    ..Circulating biomarkers can offer insight into subclinical cardiovascular stress and thus have the potential to aid in risk stratification and tailoring of therapy...
  37. ncbi Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide
    Marc S Sabatine
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Boston, Mass 02115, USA
    Circulation 105:1760-3. 2002
    ..Little is known, however, about the utility of these biomarkers in combination...
  38. ncbi Angiographic and clinical outcomes in patients receiving low-molecular-weight heparin versus unfractionated heparin in ST-elevation myocardial infarction treated with fibrinolytics in the CLARITY-TIMI 28 Trial
    Marc S Sabatine
    Thrombolysis in Myocardial Infarction TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Circulation 112:3846-54. 2005
    ..Whether these advantages translate into greater infarct-related artery patency and fewer adverse clinical events in patients with ST-elevation myocardial infarction (STEMI) receiving fibrinolytic therapy remains under study...
  39. ncbi The role of clopidogrel in early and sustained arterial patency after fibrinolysis for ST-segment elevation myocardial infarction: the ECG CLARITY-TIMI 28 Study
    Benjamin M Scirica
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 48:37-42. 2006
    ..This study was designed to determine the relationship between clopidogrel and early ST-segment resolution (STRes) and the interaction of the two with clinical outcomes after fibrinolysis...
  40. ncbi Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial
    Kausik K Ray
    Brigham and Women's Hospital/Harvard Medical School, Boston, Massachusetts, USA
    J Am Coll Cardiol 46:1417-24. 2005
    ....
  41. ncbi Streptokinase and enoxaparin as an alternative to fibrin-specific lytic-based regimens: an ExTRACT-TIMI 25 analysis
    Roberto R Giraldez
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Drugs 69:1433-43. 2009
    ....
  42. ncbi Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22
    Kausik K Ray
    TIMI Study Group, Cardiovascular Division and the Department of Medicine, Brigham and Women s Hospital Harvard Medical School, Boston, MA 02115, USA
    Arterioscler Thromb Vasc Biol 29:424-30. 2009
    ....
  43. ncbi Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction
    Elliott M Antman
    Thrombolysis in Myocardial Infarction TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    N Engl J Med 354:1477-88. 2006
    ..Unfractionated heparin is often used as adjunctive therapy with fibrinolysis in patients with ST-elevation myocardial infarction. We compared a low-molecular-weight heparin, enoxaparin, with unfractionated heparin for this purpose...
  44. ncbi B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction: an ENTIRE-TIMI-23 substudy
    Jessica L Mega
    TIMI Study Group, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 44:335-9. 2004
    ..These data support the value of combining markers of hemodynamic stress with traditional approaches to risk assessment in acute myocardial infarction...
  45. ncbi Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial
    Sean R Wilson
    Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts, USA
    J Am Coll Cardiol 53:1510-6. 2009
    ..We aimed to evaluate the efficacy and safety of ranolazine in a larger and more diverse group of patients with angina than previously studied...
  46. ncbi Relationship between nonsustained ventricular tachycardia after non-ST-elevation acute coronary syndrome and sudden cardiac death: observations from the metabolic efficiency with ranolazine for less ischemia in non-ST-elevation acute coronary syndrome-thr
    Benjamin M Scirica
    Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, and Harvard Medical School, Boston, Mass 02115, USA
    Circulation 122:455-62. 2010
    ..The incidence and prognostic implications of VT in patients with non-ST-elevation acute coronary syndrome receiving contemporary care have not been examined...
  47. ncbi Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction
    Marc S Sabatine
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
    Circulation 117:1936-44. 2008
    ....
  48. ncbi Synergistic relationship between hyperglycaemia and inflammation with respect to clinical outcomes in non-ST-elevation acute coronary syndromes: analyses from OPUS-TIMI 16 and TACTICS-TIMI 18
    Kausik K Ray
    The TIMI Study Group and Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, 350 Longwood Avenue, Boston, MA 02115, USA
    Eur Heart J 28:806-13. 2007
    ..To investigate the relationship between diabetes and inflammation and the potentially synergistic relationship between hyperglycaemia and inflammation on clinical outcomes in non ST-elevation ACS...
  49. ncbi Hemodynamic significance of periprocedural myocardial injury assessed with N-terminal pro-B-type natriuretic peptide after percutaneous coronary intervention in patients with stable and unstable coronary artery disease (from the JUMBO-TIMI 26 trial)
    Marc P Bonaca
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Am J Cardiol 99:344-8. 2007
    ..This finding supports the physiologic relevance of procedural MI and the continued effort to define therapies that decrease the risk of this complication...
  50. ncbi Prognostic utility of heart-type fatty acid binding protein in patients with acute coronary syndromes
    James A de Lemos
    Cardiovascular Division, Brigham and Women's Hospital, 350 Longwood Ave, First Floor, Boston, Mass 02115, USA
    Circulation 114:550-7. 2006
    ....
  51. ncbi Concentrations of C-reactive protein and B-type natriuretic peptide 30 days after acute coronary syndromes independently predict hospitalization for heart failure and cardiovascular death
    Benjamin M Scirica
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Department of Pathology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Clin Chem 55:265-73. 2009
    ....
  52. ncbi Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction)
    David A Morrow
    Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
    Circulation 113:1745-52. 2006
    ..At 30 days, Lp-PLA2 activity is significantly lowered with high-dose statin therapy and is associated with an increased risk of CV events independent of C-reactive protein and LDL cholesterol levels...
  53. ncbi Clinical features and outcomes of women with unstable ischemic heart disease: observations from metabolic efficiency with ranolazine for less ischemia in non-ST-elevation acute coronary syndromes-thrombolysis in myocardial infarction 36 (MERLIN-TIMI 36)
    Jessica L Mega
    Brigham and Women s Hospital, 350 Longwood Ave, 1st Floor, Boston, MA 02115, USA
    Circulation 121:1809-17. 2010
    ..In prior studies, sex-based treatment differences have been observed with the antiischemic ranolazine, with a possibly diminished effect in women...
  54. ncbi Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction
    Masahisa Shimpo
    Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass, USA
    Circulation 109:2186-90. 2004
    ..These data suggest that ST2 may be a useful biomarker and that this novel inflammatory receptor may play a role in cardiac pathophysiology...
  55. ncbi Relations between bleeding and outcomes in patients with ST-elevation myocardial infarction in the ExTRACT-TIMI 25 trial
    Robert P Giugliano
    Cardiovascular Medicine, TIMI Study Group, Brigham and Women s Hospital, 350 Longwood Avenue, 1st Floor Offices, Boston, MA 02115, USA
    Eur Heart J 31:2103-10. 2010
    ..To evaluate the association of bleeding with mortality in ST-elevation myocardial infarction (STEMI)...
  56. ncbi Myeloid-related protein 8/14 and the risk of cardiovascular death or myocardial infarction after an acute coronary syndrome in the Pravastatin or Atorvastatin Evaluation and Infection Therapy: Thrombolysis in Myocardial Infarction (PROVE IT-TIMI 22) trial
    David A Morrow
    Thrombolysis in Myocardial Infarction Study Group, Brigham and Women s Hospital, Boston, MA 02115, USA
    Am Heart J 155:49-55. 2008
    ..Elevated concentrations of MRP-8/14 are associated with a higher risk for future cardiovascular events in apparently healthy individuals but have not been assessed with respect to prognosis in patients with acute coronary syndrome...
  57. ncbi Sequential risk stratification using TIMI risk score and TIMI flow grade among patients treated with fibrinolytic therapy for ST-segment elevation acute myocardial infarction
    Dimitrios Karmpaliotis
    Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    Am J Cardiol 94:1113-7. 2004
    ..High TRS at presentation is associated with abnormal myocardial perfusion, even after adjusting for possible confounders...
  58. ncbi Correlation between the TIMI risk score and high-risk angiographic findings in non-ST-elevation acute coronary syndromes: observations from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms
    Jessica L Mega
    TIMI Study Group, Brigham and Women's Hospital, Boston, Mass 02115, USA
    Am Heart J 149:846-50. 2005
    ..These findings likely explain in part the particular benefit of potent antithrombin and antiplatelet agents among patients with higher risk scores...
  59. ncbi Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischem
    Benjamin M Scirica
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, and Harvard Medical School, 75 Francis St, Boston, MA 02115, USA
    Circulation 116:1647-52. 2007
    ..Ranolazine reduces proarrhythmic substrate and triggers such as early afterdepolarization in experimental models. However, the potential antiarrhythmic actions of ranolazine have yet to be demonstrated in humans...
  60. ncbi Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease
    Marc S Sabatine
    Cardiovascular Division, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
    Circulation 115:1528-36. 2007
    ....
  61. ncbi Prognostic value of serial B-type natriuretic peptide testing during follow-up of patients with unstable coronary artery disease
    David A Morrow
    Cardiovascular Division and Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass 2115, USA
    JAMA 294:2866-71. 2005
    ..Clinical Trials Registration ClinicalTrials.gov Identifier: NCT00251576...
  62. ncbi Assessment of adiponectin and the risk of recurrent cardiovascular events in patients presenting with an acute coronary syndrome: observations from the Pravastatin Or atorVastatin Evaluation and Infection Trial-Thrombolysis in Myocardial Infarction 22 (PR
    Sean R Wilson
    TIMI Study Group, Brigham and Women s Hospital, Boston, MA 02115, USA
    Am Heart J 161:1147-55.e1. 2011
    ..Recent data have suggested a possible discordant adverse risk relationship in acute coronary syndrome (ACS). Therefore, we investigated the association between adiponectin and cardiovascular events in patients with ACS...
  63. ncbi Early dynamic risk stratification with baseline troponin levels and 90-minute ST-segment resolution to predict 30-day cardiovascular mortality in ST-segment elevation myocardial infarction: analysis from CLopidogrel as Adjunctive ReperfusIon TherapY (CLAR
    Matthew W Sherwood
    TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Am Heart J 159:964-971.e1. 2010
    ..The incremental prognostic use of the initial magnitude of troponin elevation and its value in conjunction with ST-segment resolution (STRes) in ST elevation myocardial infarction (STEMI) is less well defined...
  64. ncbi Thrombus precursor protein and clinical outcomes in patients with acute coronary syndromes
    Jessica L Mega
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 51:2422-9. 2008
    ..We sought to test the prognostic performance of thrombus precursor protein (TpP) in patients presenting with an acute coronary syndrome (ACS)...
  65. ncbi Cholesterol, C-reactive protein, and cerebrovascular events following intensive and moderate statin therapy
    Jessica L Mega
    TIMI Thrombolysis in Myocardial Infarction Study Group, Boston, Massachusetts 12114, USA
    J Thromb Thrombolysis 22:71-6. 2006
    ..While statins have been shown to reduce cerebrovascular events (CVE), the relationship between cholesterol, C-reactive protein (CRP), and CVE in patients treated with different statin strategies is still being explored...
  66. ncbi Enoxaparin versus unfractionated heparin as antithrombin therapy in patients receiving fibrinolysis for ST-elevation myocardial infarction. Design and rationale for the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thro
    Elliott M Antman
    TIMI Study Group, Boston, MA 02115, USA
    Am Heart J 149:217-26. 2005
  67. ncbi Comparison of effects of bare metal versus drug-eluting stent implantation on biomarker levels following percutaneous coronary intervention for non-ST-elevation acute coronary syndrome
    C Michael Gibson
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital and Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA
    Am J Cardiol 97:1473-7. 2006
    ..In conclusion, patients undergoing DES implantation achieved more reductions in periprocedural markers of inflammation and necrosis than patients receiving bare metal stents among those with non-ST-elevation acute coronary syndrome...
  68. ncbi Correlates of bleeding events among moderate- to high-risk patients undergoing percutaneous coronary intervention and treated with eptifibatide: observations from the PROTECT-TIMI-30 trial
    Ajay J Kirtane
    Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical Center, USA
    J Am Coll Cardiol 47:2374-9. 2006
    ..The more widespread use of CrCl or other estimates of renal function over Cr may lead to more appropriate dose adjustments of eptifibatide...
  69. ncbi Minimal ST-segment deviation: a simple, noninvasive method for identifying patients with a patent infarction-related artery after fibrinolytic administration
    Howard A Cooper
    Cardiovascular Division, Brigham and Women s Hospital, Boston, Mass 02115, USA
    Am Heart J 144:790-5. 2002
    ..The sum of ST-segment resolution (sum-STRES) has a high positive predictive value (PPV) for a patent IRA, but is quite time-consuming...
  70. ncbi Validated risk score predicts the development of congestive heart failure after presentation with unstable angina or non-ST-elevation myocardial infarction: results from OPUS-TIMI 16 and TACTICS-TIMI 18
    John V Wylie
    Division of Cardiology, Beth Israel Deaconess Medical Center, Department of Medicine, Harvard Medical School, Boston, Mass 02215, USA
    Am Heart J 148:173-80. 2004
    ..We developed and validated a risk score to predict which patients will develop CHF...
  71. ncbi Evaluation of a novel anti-ischemic agent in acute coronary syndromes: design and rationale for the Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-elevation acute coronary syndromes (MERLIN)-TIMI 36 trial
    David A Morrow
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA
    Am Heart J 151:1186.e1-9. 2006
    ..CONCLUSIONS: MERLIN-TIMI 36 will evaluate the role of ranolazine in the acute and chronic management of patients presenting with NSTE-ACS...
  72. ncbi Troponins in acute coronary syndromes
    Benjamin M Scirica
    Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA
    Semin Vasc Med 3:363-74. 2003
    ....
  73. ncbi Troponins in acute coronary syndromes
    Benjamin M Scirica
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA
    Prog Cardiovasc Dis 47:177-88. 2004
    ..Future generations of troponin assays may detect specific posttranslational modifications of troponins that may increase the analytic sensitivity for myocardial damage and offer insight into the timing and mechanism of myocardial injury...
  74. ncbi Relation between soluble intercellular adhesion molecule-1, statin therapy, and long-term risk of clinical cardiovascular events in patients with previous acute coronary syndrome (from PROVE IT-TIMI 22)
    Kausik K Ray
    Brigham and Women's Hospital/Harvard Medical School, Boston, Massachusetts, USA
    Am J Cardiol 98:861-5. 2006
    ..In conclusion, in this large study of patients with ACS, we provide evidence that increased endothelial activation after ACS is independently associated with increased long-term risk of death, myocardial infarction, or recurrent ACS...
  75. ncbi Efficacy and safety of enoxaparin versus unfractionated heparin in patients with ST-segment elevation myocardial infarction also treated with clopidogrel
    Marc S Sabatine
    Thrombolysis in Myocardial Infarction TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital and Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 49:2256-63. 2007
    ....
  76. ncbi Global outcomes of ST-elevation myocardial infarction: comparisons of the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACT-TIMI 25) registry and trial
    Benjamin A Steinberg
    Thrombolysis in Myocardial Infarction Study Group, Cardiovascular Division, Brigham and Women s Hospital and Department of Medicine, Harvard Medical School, Boston, MA 02115, USA
    Am Heart J 154:54-61. 2007
    ..We hypothesized that adjustment for baseline risk would minimize such variations...
  77. ncbi Elevations in troponin T and I are associated with abnormal tissue level perfusion: a TACTICS-TIMI 18 substudy. Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis in Myocardial Infarction
    Graham C Wong
    Department of Medicine, Brigham and Women's Hospital, Boston, Mass, USA
    Circulation 106:202-7. 2002
    ..Independent of the presence of thrombus and abnormal flow in the epicardial artery, impaired tissue level perfusion is associated with a 1.8-fold increased risk of cTnT elevation...
  78. ncbi Soluble CD40L: risk prediction after acute coronary syndromes
    Nerea Varo
    Donald W. Reynolds Cardiovascular Clinical Research Center, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass 02115, USA
    Circulation 108:1049-52. 2003
    ..Notably, combined assessment of sCD40L with cTnI complements prognostic information for death and MI...
  79. ncbi Pathophysiology, prognostic significance and clinical utility of B-type natriuretic peptide in acute coronary syndromes
    Stephen D Wiviott
    TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA
    Clin Chim Acta 346:119-28. 2004
    ..Future research is needed to identify therapies of particular benefit for patients with ACS and natriuretic peptide elevation...
  80. ncbi National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical characteristics and utilization of biochemical markers in acute coronary syndromes
    David A Morrow
    Brigham and Women's Hospital, Harvard University, Boston, MA, USA
    Circulation 115:e356-75. 2007
  81. ncbi Predictors of initial nontherapeutic anticoagulation with unfractionated heparin in ST-segment elevation myocardial infarction
    Susan Cheng
    Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Circulation 119:1195-202. 2009
    ..Although weight-based nomograms have improved the efficacy and safety of dosing unfractionated heparin in ST-segment elevation myocardial infarction, achieving therapeutic anticoagulation in practice remains challenging...
  82. ncbi Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis
    Sabina A Murphy
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, 350 Longwood Avenue, First Floor, Boston, MA 02115, USA
    Eur Heart J 28:2077-86. 2007
    ....
  83. ncbi Early and long-term clinical outcomes associated with reinfarction following fibrinolytic administration in the Thrombolysis in Myocardial Infarction trials
    C Michael Gibson
    Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, 350 Longwood Avenue, 1st Floor, Boston, MA 02115, USA
    J Am Coll Cardiol 42:7-16. 2003
    ..We hypothesized that early recurrent myocardial infarction (MI) following fibrinolytic administration would be assessed with higher mortality at both 30 days and 2 years...
  84. ncbi Percutaneous coronary intervention in patients receiving enoxaparin or unfractionated heparin after fibrinolytic therapy for ST-segment elevation myocardial infarction in the ExTRACT-TIMI 25 trial
    C Michael Gibson
    Cardiovascular Division, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    J Am Coll Cardiol 49:2238-46. 2007
    ....
  85. ncbi Evaluation of the time saved by prehospital initiation of reteplase for ST-elevation myocardial infarction: results of The Early Retavase-Thrombolysis in Myocardial Infarction (ER-TIMI) 19 trial
    David A Morrow
    Cardiovascular Division and TIMI Study Group, Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 40:71-7. 2002
    ....
  86. ncbi Effect of thrombocytopenia on outcomes following treatment with either enoxaparin or unfractionated heparin in patients presenting with acute coronary syndromes
    Robert W Yeh
    Department of Medicine, University of California, San Francisco, San Francisco, California, USA
    Am J Cardiol 100:1734-8. 2007
    ..In conclusion, thrombocytopenia is a significant correlate of adverse events in patients presenting with non-ST-elevation ACS treated with either enoxaparin or UFH...
  87. ncbi Thrombolysis in Myocardial Infarction (TIMI) Risk Index predicts long-term mortality and heart failure in patients with ST-elevation myocardial infarction in the TIMI 2 clinical trial
    Quynh A Truong
    Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, USA
    Am Heart J 157:673-9.e1. 2009
    ..We sought to evaluate whether TRI was predictive of long-term mortality and clinical events...
  88. ncbi Angiographic perfusion score: an angiographic variable that integrates both epicardial and tissue level perfusion before and after facilitated percutaneous coronary intervention in acute myocardial infarction
    C Michael Gibson
    TIMI Study Group, The Department of Medicine, Brigham and Women's Hospital, Boston, Mass, USA
    Am Heart J 148:336-40. 2004
    ..Partial or full angiographic perfusion scores are associated with a halving of infarct size, and no patients with full angiographic perfusion died...
  89. ncbi Association of elevated B-type natriuretic peptide levels with angiographic findings among patients with unstable angina and non-ST-segment elevation myocardial infarction
    Saihari Sadanandan
    Oklahoma University Health Sciences Center, Oklahoma City, Oklahoma, USA
    J Am Coll Cardiol 44:564-8. 2004
    ..We hypothesized that elevated B-type natriuretic peptide (BNP) levels would be associated with a greater severity of angiographic disease and a greater extent of myocardium at risk...
  90. ncbi Long-term prognostic value of neopterin: a novel marker of monocyte activation in patients with acute coronary syndrome
    Kausik K Ray
    Department of Public Health and Primary Care, University of Cambridge, Worts Causeway, Cambridge, CB1 8RN, United Kingdom
    Circulation 115:3071-8. 2007
    ..Neopterin is a soluble marker of monocyte activation, and elevated levels are of prognostic value in patients with stable coronary artery disease...
  91. ncbi Use of natriuretic peptides in clinical decision-making for patients with non-ST-elevation acute coronary syndromes
    James A de Lemos
    Am Heart J 153:450-3. 2007
  92. ncbi National Academy of Clinical Biochemistry Laboratory Medicine practice guidelines: Clinical utilization of cardiac biomarker testing in heart failure
    W H Wilson Tang
    Circulation 116:e99-109. 2007
  93. ncbi Brain natriuretic peptide measurement in acute coronary syndromes: ready for clinical application?
    James A de Lemos
    Circulation 106:2868-70. 2002
  94. ncbi Assessing the success of fibrinolysis: can we let the interventionalist rest?
    David A Morrow
    Am Heart J 145:380-2. 2003
  95. ncbi National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine practice guidelines: Analytical issues for biomarkers of heart failure
    Fred S Apple
    Hennepin County Medical Center, Minneapolis, Minn, USA
    Circulation 116:e95-8. 2007
  96. ncbi Combining natriuretic peptides and necrosis markers in the assessment of acute coronary syndromes
    James A de Lemos
    Donald W. Reynolds Cardiovascular Clinical Research Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA
    Rev Cardiovasc Med 4:S37-46. 2003
    ..In the future, multimarker strategies that incorporate panels of cardiac biomarkers are likely to be used for risk stratification and for pathophysiology-guided treatment in patients with ACS...
  97. ncbi Noninvasive assessment of reperfusion therapy: slow progress towards a worthwhile goal
    James A de Lemos
    Am Heart J 146:747-9. 2003
  98. ncbi Prognostic implications of elevated troponin in patients with suspected acute coronary syndrome but no critical epicardial coronary disease: a TACTICS-TIMI-18 substudy
    Hisham Dokainish
    Section of Cardiology, Baylor College of Medicine, Houston, Texas 77030, USA
    J Am Coll Cardiol 45:19-24. 2005
    ..CONCLUSIONS: Elevated troponin in ACS is associated with a higher risk for death or reinfarction, even among patients who do not have significant angiographic CAD. The mechanisms conferring this adverse prognosis merit further study...
  99. ncbi Future of biomarkers in acute coronary syndromes: moving toward a multimarker strategy
    David A Morrow
    Circulation 108:250-2. 2003
  100. ncbi Prognostic value of N-terminal pro-atrial and pro-brain natriuretic peptide in patients with acute coronary syndromes
    Torbjørn Omland
    Department of Cardiology, The National Hospital, Oslo, Norway
    Am J Cardiol 89:463-5. 2002
  101. ncbi Association among plasma levels of monocyte chemoattractant protein-1, traditional cardiovascular risk factors, and subclinical atherosclerosis
    Rajat Deo
    Donald W. Reynolds Cardiovascular Clinical Research Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA
    J Am Coll Cardiol 44:1812-8. 2004
    ..These findings support the potential role of MCP-1 as a biomarker target for drug development...